Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 June 2020 | Story Charlene Stanley
International studies group
Dr Kundai Manamere and Dr Hlengiwe Dlamini

The International Studies Group continues to keep critical issues in Africa on the research agenda, with two of its postdoctoral research fellows awarded prestigious international research grants.

Dr Hlengiwe Dlamini won a CODESRIA (Council for the Development of Social Science Research in Africa) award as part of the organisation’s ‘Meaning-making Research Initiatives’. These initiatives focus on supporting research that contributes to agendas for imagining, planning, and creating African futures.

“I was over the moon when I heard that I received this award!” says an excited Dr Dlamini. “The competition was a tough one. Applications were received from 430 female applicants and just 12 were retained, including mine.”  
 
Her colleague in the ISG, Dr Kundai Manamere, who recently signed a book contract with Ohio University Press, has been awarded an African Peacebuilding Network (APN) 2020 Individual Research Fellowship, administered by the American Social Science Research Council.

“I am delighted to have received this award. As an early-career scholar, this is one of my several goals, and achieving it recognises and validates my work. This boosts my confidence and encourages me to keep working hard,” says Dr Manamere.

Examining border disputes
Dr Dlamini’s research project is a comparative study of two border disputes – between Cameroon and Nigeria over the Bakassi Peninsula borderland, and between Eswatini (formerly Swaziland) and South Africa over the demarcation of their borders, and how the international doctrine of uti possidetis juris, as an instrument of inter-state conflict resolution, applies to these disputes.

“The doctrine of uti possidetis juris (literally translated: as you possess, thus may you possess) states that frontiers inherited from colonialism cannot be changed under any circumstance. Cameroon won its case in the International Court of Justice in 2002 in its border dispute with Nigeria and this had a direct impact on Eswatini, which also had a border dispute with South Africa,” she explains.

“The post-apartheid South African governments have been hostile to the idea of adjusting their borders with Eswatini, while the Eswatini monarchy has relentlessly been pursuing what it calls ‘its stolen territories by the British and the Boers in the 19th century’.”

Dr Dlamini will be heading a team of four female researchers from different nationalities. As soon as international flights resume, two scholars from Canada and Sweden will head for Cameroon, while she and another researcher will start with archival research in Southern Africa, before embarking on fieldwork.

“There will be no rest for us. It is incumbent on me to assemble the data collected and use it to write two or three scholarly articles for journal publications,” says Dr Dlamini.


Migration issues and public health interventions
Dr Manamere’s research focuses on documenting the experiences of former refugees and their host communities at Chambuta refugee camp, one of the five refugee camps established by the Zimbabwean government along the Mozambican border in the 1980s to accommodate asylum seekers fleeing from the Mozambican civil war.
“The project explores their experiences and examines their perceptions about conflict, displacement, refugee conditions, and the occurrence of diseases and intervention following a disease outbreak that killed nearly 200 people in August 1992. I use the Chambuta case to reflect on the politics of voice and representation in history – how official reports by governments and non-governmental organisations overshadow the experiences of refugees and host communities.”

The COVID-19 lockdowns in both South Africa and Zimbabwe have delayed Dr Manamere’s fieldwork plans. She will now first spend time collecting information from digitised archives and doing telephonic and online interviews.

ISG a melting pot for international research talent
Both researchers expressed their appreciation for the role the ISG has played in shaping their academic careers.
“By creating opportunities for me to network with renowned historians in my field, the ISG has expanded my circle of mentors. All these opportunities culminated into several achievements, including this award, forthcoming articles in leading international journals, presentations at international conferences, and a book due to be published by the Ohio University Press, one of the leading Africanist publishers in the world. To me, this is the best foundation for a successful academic career, and I am proud to be part of the group,” says Dr Manamere.

“The ISG creates one of the most convivial environments for intellectual production.  We are really flying high. The scholars of the ISG are making their mark in different ways. I am very grateful for the Stanley Trapido seminar series and other academic activities that constitute a vital crucible for the cross-fertilisation of our minds and for the acquisition of new methodologies and updates in our disciplines,” says Dr Dlamini.

Prof Ian Phimister, Head of the ISG, says the two researchers have brought great credit to the UFS and the ISG.“By winning such prestigious awards, Drs Dlamini and Manamere show themselves to be first-rate scholars. Their academic commitment and drive are exemplary. At the same time, their research projects, respectively on comparative African territorial boundary disputes and on Mozambican refugees' experiences of civil war, drought, and disease, have significant policy-making implications.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept